SCHEMBL18123

SCHEMBL18123

CCCC1C(=O)NCCN1C[C@H]1CN(S(=O)(=O)c2cccs2)CCN1

nearest known ligand 0.39

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
PKM P14618 4/20 0.39
MEN1 O00255 3/20 0.37
KMT2A Q03164 3/20 0.37
KDM4E B2RXH2 1/20 0.37
ALDH1A1 P00352 2/20 0.36
POLB P06746 2/20 0.36
TSHR P16473 2/20 0.36
MAPK1 P28482 1/20 0.36
BACE1 P56817 1/20 0.36
NPC1 O15118 2/20 0.36
RAB9A P51151 1/20 0.36
LMNA P02545 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
HTT P42858 1/20 0.36
GCKR Q14397 1/20 0.36
GAA P10253 2/20 0.35
MAPT P10636 2/20 0.35
USP2 O75604 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18121 0.84 PKM (0.42) PKMMEN1KMT2AKDM4EALDH1A1
SCHEMBL18134 0.81 ALDH1A1 (0.30) KDM4EALDH1A1POLBLMNAMAPT
SCHEMBL16813 0.76 PKM (0.41) PKMMEN1KMT2AKDM4EALDH1A1
SCHEMBL12089519 0.76 PKM (0.45) PKMMEN1KMT2AKDM4EALDH1A1
SCHEMBL17345 0.75 GCK (0.64) GCKR
SCHEMBL16866 0.74 GCKR (0.55) PKMMEN1KMT2AKDM4EALDH1A1
SCHEMBL25123 0.74 GCKR (0.53) GCKR
Hydrochloric Acid SCHEMBL23483 0.74 GCKR (0.55) PKMMEN1KMT2AKDM4EALDH1A1
SCHEMBL12093378 0.73 PKM (0.44) PKMMEN1KMT2AKDM4EALDH1A1
SCHEMBL17416 0.71 ALDH1A1 (0.62) PKMMEN1KMT2AALDH1A1POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2609081-A1 SULFONYLPIPERAZINE DERIVATIVES THAT INTERACT WITH GLUCOKINASE REGULATORY PROTEIN FOR THE TREATMENT OF DIABETES Amgen Inc. (US) 2013-07-03 EP disclosed
WO-2012027261-A1 SULFONYLPIPERAZINE DERIVATIVES THAT INTERACT WITH GLUCOKINASE REGULATORY PROTEIN FOR THE TREATMENT OF DIABETES AMGEN INC. (US) 2012-03-01 WO disclosed